



RECEIVED
APR 15 2002
TECH CENTER 1600 2002

SEQUENCE LISTING

<110> STEM CELL PHARMACEUTICALS, INC.
TWARDZIK, Daniel R.
FELKER, Thomas S.
PERNET, Andre
PASKELL, Stefan

<120> TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE
THEREFOR

<130> STEM1110-4

<140> US 10/039,119
<141> 2002-01-04

<150> US 09/641,587
<151> 2000-08-17

<150> US 09/492,935
<151> 2000-01-27

<150> US 09/387,567
<151> 1999-08-19

<160> 7

<170> PatentIn version 3.0

<210> 1
<211> 50
<212> PRT
<213> Homo sapiens

<400> 1

Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys
20 25 30

Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu
35 40 45

Leu Ala
50

<210> 2
<211> 50
<212> PRT
<213> Rattus norvegicus

<400> 2

Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys
20 25 30

Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu

35

40

45

Asp Ala
50

<210> 3
<211> 57
<212> PRT
<213> Artificial sequence

<220>
<223> A modified human TGF-alpha sequence

<400> 3

Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro
1 5 10 15

Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val
20 25 30

Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala
35 40 45

Arg Cys Glu His Ala Asp Leu Leu Ala
50 55

<210> 4
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial peptide sequence

<220>
<221> VARIANT
<222> (1)..(10)
<223> Xaa at residue 1, 5, 7 to 9 is independently V, G or A; Xaa at residue 6 is Y or F; and Xaa at residue 10 is R or K

<400> 4

Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 5
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> Artificial peptide sequence

<220>
<221> VARIANT
<222> (1)..(7)
<223> Xaa at residue 1 and 4 is E or D; Xaa at residue 3 and 7 is V, G, or A; Xaa at residue 5 is L or I; and Xaa at residue 6 is D or E

<400> 5

Xaa His Xaa Xaa Xaa Xaa Xaa
1 5

<210> 6

<211> 18

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial peptide sequence

<220>

<221> VARIANT

<222> (1)...(18)

<223> Xaa at residue 1, 5, 7-9, 14, 18 is indep. V, G, or A; Xaa at residue 6 is Y or F; Xaa at residue 10 is R or K; Xaa at residue 12, 15 is indep. E or D; Xaa at residue 16 is L or I; Xaa at residue 17 is D or E

<400> 6

Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa
1 5 10 15

Xaa Xaa

<210> 7

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> Artificial peptide sequence

<220>

<221> VARIANT

<222> (1)...(7)

<223> Xaa at residue 1 and 2 is indep. V, G, and A; Xaa at residue 7 is K or D

<400> 7

Xaa Xaa Ser His Phe Asn Xaa
1 5